First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup><i>G12C</i></sup> Solid Tumors (KRYSTAL-1) - Concepedia

Concepedia

Publication | Open Access

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup><i>G12C</i></sup> Solid Tumors (KRYSTAL-1)

DOI Full Paper Access

287

Citations

7

References

2022

Year

Sai‐Hong Ignatius Ou, Pasi A. Jänne, Ticiana Leal, Igor I. Rybkin, Joshua K. Sabari, Minal Barve, Lyudmila Bazhenova, Melissa L. Johnson, Karen Velastegui, Cornelius Cilliers,

Journal of Clinical Oncology

Abstract

Adagrasib 600 mg twice a day was well tolerated and exhibited antitumor activity in patients with advanced solid tumors harboring the <i>KRAS</i><sup><i>G12C</i></sup> mutation.

References

	Year	Citations

Page 1